<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">7947102</article-id><article-id pub-id-type="pmc">2033527</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nichols</surname><given-names>P. H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ward</surname><given-names>U.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ramsden</surname><given-names>C. W.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Primrose</surname><given-names>J. N.</given-names></name></contrib></contrib-group><aff>Department of Clinical Medicine, St James's University Hospital, Leeds, UK.</aff><pub-date pub-type="ppub"><month>11</month><year>1994</year></pub-date><volume>70</volume><issue>5</issue><fpage>946</fpage><lpage>949</lpage><abstract><p>Interferon alpha (IFN-alpha) enhances the activity of 5-fluorouracil (5-FU) in the treatment of advanced colorectal cancer although the mechanism is not understood. We have investigated the effect of this combination on cellular immunity and compared this with standard therapy of 5-FU/L-leucovorin, in 24 patients with advanced colorectal cancer. This study has demonstrated an enhancement of the cellular immune response in patients given 5-FU/IFN-alpha with augmentation of natural killer (NK) cell function and abrogation of 5-FU-induced suppression of lymphokine-activated killer (LAK) cell activity.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00057-0168.tif" xlink:title="scanned-page" xlink:role="946" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00057-0169.tif" xlink:title="scanned-page" xlink:role="947" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00057-0170.tif" xlink:title="scanned-page" xlink:role="948" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00057-0171.tif" xlink:title="scanned-page" xlink:role="949" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

